Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Keywords: 131I tositumomab; 51 integrin; Bevacizumab; Bexxar; Carbonic Anhydrase Isotype IX; Carcinoembryonic Antigen; Cetuximab; DNA single strand breaks; DNA/histone H1 Associated Protein; Doxorubicin; Epidermal Growth Factor; Filgrastim; Ganglioside 2; Hepatocyte Growth Factor Receptor; Ketoconazole; Labetuzuma; Melanin; Mesenchymal Epithelial Transition Factor; Mucin 1; Panitumumab; Prostate-Specific Membrane Antigen; Radioimmunotherapy; Rituximab; Tenascin-C; Tositumomab; Trastuzumab; Tumor Associated Glycoprotein; Zevalin; anti-neuropilin; antibody dependent cellular cytotoxicity; antigen; complement dependent cytotoxicity; double strand breaks; epidermal growth factor-like domain 7; lymphoma; non-Hodgkins; radioimmunotherapy; radiolabeled antibody; relative biological effectiveness; solid tumor; tumor endothelial marker 1; v3 integrin; vincristine
Document Type: Research Article
Publication date: January 1, 2011
- The aim of Current Drug Delivery is to publish peer-reviewed articles, short communications, short and in-depth reviews in the rapidly developing field of drug delivery. Modern drug research aims to build in delivery properties of a drug at the design phase, however in many cases this ideal cannot be met and the development of delivery systems becomes as important as the development as the drugs themselves.
The journal aims to cover the latest outstanding developments in drug and vaccine delivery employing physical, physico-chemical and chemical methods. The drugs include a wide range of bioactive compounds from simple pharmaceuticals to peptides, proteins, nucleotides, nucleosides and sugars. The journal will also report progress in the fields of transport routes and mechanisms including efflux proteins and multi-drug resistance.
The journal is essential for all pharmaceutical scientists involved in drug design, development and delivery.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites